In the quest to unravel the complexities of Alzheimer’s disease (AD), a decade’s worth of research has spotlighted an elusive but promising biomarker: the plasma neurofilament light chain, commonly abbreviated as NfL. This protein fragment, originating from the structural framework of neurons, is now emerging as a critical indicator of neuroaxonal injury. A recent comprehensive mini-review published in Brain Medicine synthesizes findings across diverse patient cohorts and scientific disciplines, revealing that plasma NfL not only signals neuronal damage but does so with a marked sex-specific nuance—meaning the identical plasma concentration may have drastically different implications for men and women.
Neurofilament light chain is a fundamental component of the neuronal cytoskeleton, particularly concentrated in the axons, which are the elongated projections responsible for transmitting nerve impulses. When axons deteriorate or rupture—a hallmark event in neurodegenerative diseases—NfL molecules escape into the bloodstream. Unlike traditional biomarkers such as amyloid-beta or tau proteins, which first indicate the presence of pathological hallmarks of AD, NfL provides a dynamic readout of ongoing neurodegeneration. Clinicians have long sought minimally invasive yet reliable markers that could track disease progression sequentially, and here, plasma NfL signifies a revolutionary advancement.
Despite the promise of NfL as a biomarker, the clinical interpretation of its plasma levels has been confounded by heterogeneous responses, particularly the underappreciated effects of biological sex on its diagnostic value. The recent synthesis underscores that, across several racially and ethnically diverse populations, men exhibit a sharper cognitive and structural brain decline than women for comparable NfL increases. This phenomenon suggests that plasma NfL isn’t a universal yardstick but rather a sex-modified biomarker, which could transform personalized medicine approaches for AD and related neurodegenerative diseases.
Such findings challenge the traditional one-size-fits-all approach in interpreting biomarker data. The clinical implication is profound: a plasma NfL concentration formerly considered moderate might in fact denote a significantly advanced neurodegenerative process in men when juxtaposed with women. This sex-dependent variance could partly explain some inconsistencies in previous research, where studies either found no difference or contradictory trends between men and women in fluid biomarkers. The interplay between NfL and sex-specific brain physiology reveals the intricate biological tapestry underlying neurodegeneration.
Technological innovations enabling ultrasensitive assays for blood-based NfL monitoring have fueled this breakthrough. Unlike PET imaging or cerebrospinal fluid collection—both costly, invasive, and logistically challenging—plasma NfL measurement involves a simple blood draw, allowing repeated assessments over time. This capability is transformative for clinical trials and patient management, enabling real-time tracking of disease progression and response to therapeutics across prodromal and preclinical stages. Remarkably, in familial AD carriers, NfL elevations can be detected years before symptom onset, offering a window into the earliest neuronal distress and an opportunity for preemptive intervention.
The mechanisms underlying the sex differences in plasma NfL’s prognostic power remain a subject of ongoing investigation. Hypotheses point towards microglial activity variations—brain immune cells that exhibit sex-specific inflammatory responses—as potential contributors to differential neuronal vulnerability. Hormonal factors, namely estrogen’s purported neuroprotective effects and testosterone’s modulating influence on brain aging, also emerge as plausible modulators. Additionally, men’s larger brain volume and higher white matter content may influence metabolite release and clearance dynamics, a concept aligned with the brain reserve theory. However, peripheral factors like blood-brain barrier permeability or renal clearance have been considered less likely to explain these observations, as they do not convincingly account for differences in neurodegeneration severity correlations.
This nuanced understanding of NfL as a dynamic and sex-influenced biomarker underscores the biological complexity of Alzheimer’s disease and challenges simplistic diagnostic paradigms. It highlights the necessity for large-scale, sex-stratified normative datasets across diverse demographics to establish individualized biomarker trajectories. Only then can clinicians accurately interpret plasma NfL levels within the context of sex, age, and disease stage. The review calls for future studies that consider these variables to optimize diagnostic precision and tailor therapeutic strategies accordingly.
Moreover, the question persists as to whether pharmacological interventions might modulate neuronal injury differently in men versus women. As our understanding deepens, sex-specific therapeutic responses may partially explain the variable efficacy observed in clinical trials and pave the way for personalized treatment algorithms. Integrating sex as a biological variable in neurodegenerative research and clinical practice emerges not as a choice but a requisite for scientific rigor and equitable health care.
At the heart of these insights lies an invitation to reimagine biomarker interpretation not as a static figure but as a fluid dialogue between biological sex, neuronal integrity, and disease progression. The blood itself remains an objective medium, but the meaning we extract from it demands careful contextualization. This paradigm shift has implications beyond Alzheimer’s, potentially reshaping biomarker utility across the spectrum of neurological disorders where neurodegeneration is a common thread.
The mini-review, authored by researchers from Fudan University and Wuhan University, showcases the power of interdisciplinary collaboration and meta-analysis to clarify complex biomedical phenomena. It redefines plasma NfL’s role within the AT(N) biomarker framework, cementing its position as the critical “N”—neurodegeneration indicator—complementing amyloid and tau pathology markers. This synthesis also illuminates gaps in knowledge and practical hurdles, including assay standardization and accessibility in resource-limited settings, which must be addressed to fully realize plasma NfL’s clinical potential globally.
As the search for effective Alzheimer’s diagnostics and treatments continues, plasma NfL offers a beacon of hope. It promises earlier detection, nuanced risk stratification, and individualized monitoring of neuroaxonal injury—provided that the scientific and medical communities embrace the imperative for sex-specific interpretation. Beyond raw numbers, this approach advocates for listening attentively to the structural whispers of the brain, tuned finely to the complexities of human biology.
Subject of Research: People
Article Title: Plasma neurofilament light chain: A biomarker for neuronal injury in Alzheimer’s disease and the imperative for sex-specific interpretation
News Publication Date: 30 June 2026
Web References:
https://doi.org/10.61373/bm026y.0051
References:
Xia Y, Yuan P, Fei G, Cheng X. Plasma neurofilament light chain: A biomarker for neuronal injury in Alzheimer’s disease and the imperative for sex-specific interpretation. Brain Medicine 2026. DOI: https://doi.org/10.61373/bm026y.0051
Image Credits:
Xiaoqin Cheng
Keywords:
Neurofilament light chain, Alzheimer’s disease, biomarker, plasma NfL, neurodegeneration, sex differences, neuroaxonal injury, diagnostic biomarker, brain reserve, cognitive decline, amyloid, tau, personalized medicine
Tags: Alzheimer’s disease progression trackingAlzheimer’s disease biomarker validationAlzheimer’s disease plasma biomarkersminimally invasive Alzheimer’s diagnosticsneuroaxonal injury detectionneurofilament light chain clinical implicationsneurofilament light chain sex differencesNfL protein in neurodegenerative diseasesplasma neurofilament light chain researchplasma NfL neurodegeneration indicatorsex disparities in neurodegenerative biomarkerssex-specific Alzheimer’s disease markers
